BeOne Medicines Transitions to Direct Operations in Israel
Translated & summarized from Maariv by baba
BeOne Medicines is transitioning to direct operations in Israel after six years, signifying a new phase of global expansion. Roey Eliya has been appointed CEO of BeOne Medicines in Israel, leading strategy and local operations. The company, a global oncology firm, will continue its focus on hematology while expanding into solid tumors, aiming to increase patient access to innovative cancer treatments.
The story in 5 lines · by baba
- BeOne Medicines is moving to direct operations in Israel after six years.
- Roey Eliya appointed CEO of BeOne Medicines in Israel.
- The company focuses on oncology and hematology treatments.
- BeOne is expanding its efforts into solid tumor treatments.
- The move reflects BeOne's global expansion and development.
BeOne Medicines is shifting to direct operations in Israel, marking a new phase after six years of activity in the country and reflecting the company's ongoing global expansion. Roey Eliya will lead BeOne's strategy and operations in Israel, responsible for developing the local organization and managing relationships with the Israeli healthcare system. Eliya, who holds an MBA in Financial Management from Tel Aviv University and is a certified public accountant, brings over 20 years of management experience in pharmaceuticals, diagnostics, medical nutrition, consumer products, and consulting.
Throughout his career in the pharmaceutical industry, Eliya held senior management positions in commercial and market access roles, overseeing both strategy and operational implementation in complex organizations. He has successfully led extensive commercial portfolios and played a key role in launching innovative treatments in oncology, rare diseases, and vaccines, promoting sustainable growth and expanding patient access to treatments in multiple markets.
"I am happy to join BeOne at a significant stage in its development in Israel. Our aspiration to make innovative cancer treatments accessible to more patients is more important today than ever, and I am proud to take part in advancing this mission," said Eliya. "I am joining an excellent local team, and together we will work to strengthen BeOne's presence in Israel, deepen collaborations with the healthcare system, and create a significant and lasting impact for patients."
BeOne is a global oncology company driven by scientific excellence, aiming to reach more patients rapidly. Since its inception, the company has challenged conventions in discovering, developing, and delivering cancer treatments. Its end-to-end internal system covers research, development, manufacturing, and commercialization, enabling swift progress from concept to impact. In Israel, BeOne has already established operations in hematology, which will remain a core focus. The company also aims to deepen its contribution to oncology and expand cooperation with healthcare professionals, patient organizations, and other local entities. Concurrently, BeOne is making initial steps in solid tumors, reinforcing its commitment to bringing innovative treatments to cancer patients with unmet medical needs.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
